Paracetamol ( DrugBank: Paracetamol )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
3	脊髄性筋萎縮症	2
6	パーキンソン病	1
13	多発性硬化症／視神経脊髄炎	5
35	天疱瘡	1
46	悪性関節リウマチ	8
49	全身性エリテマトーデス	2

3. 脊髄性筋萎縮症

臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03648658 (ClinicalTrials.gov)	February 18, 2019	8/8/2018	Paracetamol Study in Patients With Low Muscle Mass	Pharmacokinetics and Safety of Treatment With Paracetamolin Children and Adults With Spinal Muscular ...	SMA II;Cerebral Palsy	Drug: Paracetamol 120Mg/5mL Oral Suspension	Mette Cathrine Oerngreen	Elsass Foundation	Recruiting	6 Years	45 Years	All	48	Phase 4	Denmark
2	EUCTR2018-002295-40-DK (EUCTR)	11/09/2018	11/07/2018	Is treatment with the painkiller paracetamolsafe in patients with spinal muscular atrophy and cerebr ...	Pharmacokinetics and safety of treatment with paracetamolin children and adults with spinal muscular ...	Spinal muscular atrophy type II (SMA II)Cerebral palsy (CP);Therapeutic area: Diseases [C] - Nervous ...	INN or Proposed INN: Paracetamol Other descriptive name: PARACETAMOL	Copenhagen Neuromuscular Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 1;Phase 4	Denmark

First Previous1Next Last

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02305017 (ClinicalTrials.gov)	March 2014	28/11/2014	Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers	Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers	Parkinson's Disease	Drug: BIA 9-1067;Drug: Paracetamol	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	28	Phase 1	NULL

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04688788 (ClinicalTrials.gov)	April 28, 2021	22/12/2020	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Compa ...	Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive ...	Drug: Rituximab;Drug: Ocrelizumab;Drug: Fexofenadine;Drug: Paracetamol;Drug: Methylprednisolone	Rigshospitalet, Denmark	Odense University Hospital;Aarhus University Hospital;Aalborg University Hospital;Herlev Hospital;Hi ...	Recruiting	18 Years	65 Years	All	594	Phase 3	Denmark
2	EUCTR2017-004702-17-IT (EUCTR)	07/11/2018	04/11/2020	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjec ...	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg ...	Multiple sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10028053;Term: MS;System Orga ...	Trade Name: FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE Product Name: Formistin 10 mg ...	NOVARTIS PHARMA AG	NULL	Not Recruiting			Female: yes Male: yes	284	Phase 2	United States;Czechia;Estonia;Spain;Lithuania;Austria;Russian Federation;Italy;Czech Republic;Poland ...
3	NCT03368664 (ClinicalTrials.gov)	October 24, 2017	2/11/2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRM ...	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safe ...	Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;D ...	Genzyme, a Sanofi Company	NULL	Active, not recruiting	10 Years	17 Years	All	50	Phase 3	Austria;Belgium;France;Italy;Netherlands;Poland;Portugal;Russian Federation;Turkey;United Kingdom;Bu ...
4	NCT02583594 (ClinicalTrials.gov)	December 6, 2015	16/10/2015	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multipl ...	A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Ph ...	Progressive Multiple Sclerosis	Drug: Acyclovir;Drug: Methylprednisolone;Drug: alemtuzumab GZ402673;Drug: Paracetamol;Drug: Loratadi ...	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	All	24	Phase 1	Spain
5	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Assoc ...	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovi ...	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain

First Previous1Next Last

先頭へ

35. 天疱瘡

臨床試験数 : 99 / 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02613910 (ClinicalTrials.gov)	December 23, 2015	23/11/2015	Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris	OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With ...	Pemphigus	Drug: Ofatumumab;Drug: Acetaminophen/paracetamol;Drug: Antihistamine (cetirizine or equivalent);Drug ...	GlaxoSmithKline	NULL	Terminated	N/A	N/A	All	1	Phase 3	United States

First Previous1Next Last

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003333-95-LT (EUCTR)	21/07/2016	09/05/2016	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Ar ...	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimu ...	Stroke (ischaemic stroke or intracerebral hemorrhage) MedDRA version: 22.1;Level: PT;Classification ...	Trade Name: Paracetamol Product Name: Paracetamol INN or Proposed INN: Paracetamol Other descriptive na ...	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting	Female: yes Male: yes	1500	Phase 3	Greece;Netherlands;Hungary;Norway;Poland;Italy;United Kingdom;Germany;Estonia
2	EUCTR2011-002633-19-DE (EUCTR)	21/12/2011	02/08/2011	Prednisolone test for patients with an inflammatory joint disease	Diagnostic value of oral prednisolone test for rheumatoid arthritis - RZR12011-TryCort	rheumatoid arthritis MedDRA version: 14.0;Level: LLT;Classification code 10062719;Term: Seronegative ...	Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Paracetamol INN or Proposed ...	Rheumazentrum Ruhrgebiet	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes			Germany
3	EUCTR2006-004062-13-IT (EUCTR)	18/07/2006	30/08/2006	Randomised, open label, no profit, clinical, multicenter study of phase II and IIIB to assess effica ...	Randomised, open label, no profit, clinical, multicenter study of phase II and IIIB to assess effica ...	RHEUMATOID ARTHRITIS MedDRA version: 6.1;Level: PT;Classification code 10039073	Trade Name: DEPALGOS*20+325MG 28CPR RP INN or Proposed INN: OXICODONE DC.IT INN or Proposed INN: PARAC ...	A.U.S.L. RIMINI	NULL	Not Recruiting	Female: yes Male: yes	149	Phase 2	Italy
4	EUCTR2004-000074-31-BE (EUCTR)	15/03/2005	07/07/2004	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	rheumatoid arthritis MedDRA version: 7.0;Level: LLT;Classification code 10039073	Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyri ...	Merck Sharp & Dohme BV	NULL	Not Recruiting	Female: yes Male: yes	150	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Belgium;Sweden
5	EUCTR2004-004302-24-CZ (EUCTR)	09/03/2005	04/02/2005	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	Rheumatoid Arthritis MedDRA version: 7.0;Level: LLT;Classification code 10039073	Product Name: L-000883191 Product Code: L-000883191 INN or Proposed INN: NA Other descriptive name: NA T ...	Merck & Co., Inc.	NULL	Not Recruiting	Female: yes Male: yes	136	Phase 2	Czech Republic;Finland;Spain;Germany;Italy
6	EUCTR2004-004302-24-ES (EUCTR)	16/02/2005	04/11/2005	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	Rheumatoid Arthritis MedDRA version: 7.0;Level: LLT;Classification code 10039073	Product Name: L-000883191 Product Code: L-000883191 INN or Proposed INN: NA Other descriptive name: NA T ...	Merck & Co. Inc.	NULL	Not Recruiting	Female: yes Male: yes	136	Phase 2	Czech Republic;Finland;Spain;Germany;Italy
7	EUCTR2004-004302-24-FI (EUCTR)	18/01/2005	17/11/2004	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	Rheumatoid Arthritis MedDRA version: 7.0;Level: LLT;Classification code 10039073	Product Name: L-000883191 Product Code: L-000883191 INN or Proposed INN: NA Other descriptive name: NA T ...	Suomen MSD Oy	NULL	Not Recruiting	Female: yes Male: yes	136		Finland;Czech Republic;Germany;Spain;Italy
8	EUCTR2004-000074-31-SE (EUCTR)	06/07/2004	21/05/2004	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, S ...	rheumatoid arthritis MedDRA version: 7.0;Level: LLT;Classification code 10039073	Product Name: 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyri ...	Merck Sharp & Dohme (Sweden) AB	NULL	Not Recruiting	Female: yes Male: yes	150		Sweden

First Previous1Next Last

先頭へ

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04702256 (ClinicalTrials.gov)	December 9, 2021	30/11/2020	Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticoste ...	Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicen ...	Lupus Nephritis;Systemic Lupus Erythematosus (SLE)	Drug: Obinutuzumab administration;Drug: Administration of Methylprednisolone + Prednisone + Mycophen ...	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG	Recruiting	14 Years	N/A	All	196	Phase 3	France
2	NCT04963296 (ClinicalTrials.gov)	October 26, 2021	7/7/2021	A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Eryt ...	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficac ...	Systemic Lupus Erythematosus	Drug: Obinutuzumab;Drug: Placebo;Drug: Acetaminophen/Paracetamol;Drug: Diphenhydramine hydrochloride ...	Hoffmann-La Roche	NULL	Recruiting	18 Years	75 Years	All	200	Phase 3	United States;Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South ...

First Previous1Next Last

先頭へ